JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Overview Fund Activity
Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

58 hedge funds and large institutions have $270M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.45%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
%
% of All Funds
0.07%
New
58
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
1
Fidelity Investments
Massachusetts
$82.4M
2
Wellington Management Group
2
Wellington Management Group
Massachusetts
$34.8M
3
RG
3
Redmile Group
California
$22.5M
4
PI
4
Pharmstandard International
Luxembourg
$14.6M
5
OFM
5
Omega Fund Management
Massachusetts
$12.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Shares
Change %
SO
51
STRS Ohio
Ohio
$41K +$41K +1,900 New
AIM
52
ARK Investment Management
Florida
$40K +$40K +1,811 New
Barclays
53
Barclays
United Kingdom
$31K +$31K +1,400 New
Legal & General Group
54
Legal & General Group
United Kingdom
$27K +$27K +1,230 New
Bank of America
55
Bank of America
North Carolina
$26K +$26K +1,162 New
UBS Group
56
UBS Group
Switzerland
$24K +$24K +1,110 New
AIP
57
Ameritas Investment Partners
Nebraska
$14K +$14K +620 New
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$9K +$9K +400 New
FMA
59
FNY Managed Accounts
New York
$9K +$9K +440 New
1 2
3